RIP pharma stocks… pic.twitter.com/tWdhtlfTw4
— Ross Hendricks (@Ross__Hendricks) May 11, 2025
Donald Trump has signed an executive order to cut U.S. prescription drug prices by 30% to 80%, and the pharmaceutical industry is bracing for a financial hit when markets open. The Most Favored Nation policy ensures that Americans will pay no more than the lowest price available in other countries, breaking a system that allowed drug companies to charge higher rates in the U.S. while keeping prices low elsewhere.
For decades, consumers have paid five to ten times more for the same medications sold overseas. Trump’s order forces pharmaceutical companies to adjust their pricing or lose access to the U.S. market, putting them in a position where they must either sacrifice profits or lose customers. The announcement was made on Truth Social, where Trump declared the policy “one of the most consequential acts of my presidency.”
Investors are watching closely. Pharmaceutical stocks have remained stable since the announcement, but analysts warn that a sharp drop is likely when markets open as investors react to expected revenue losses. The sell-off could be severe, particularly for companies that rely heavily on the U.S. market for drug sales.
Industry executives are preparing legal challenges, arguing that high drug prices are necessary to fund research and development, but critics have pointed out that much of this funding comes from taxpayer-backed grants and subsidies. Public opinion strongly favors price reductions, and the legal battle ahead may not be enough to stop the policy from taking effect.
Global markets may feel the impact as well. Pharmaceutical firms could shift their pricing strategies in other countries to offset expected revenue losses, which may result in higher drug costs elsewhere. For American consumers, the immediate outcome is clear—prescription prices are set to drop.
SOURCES:
https://www.newsweek.com/donald-trump-vows-reduce-prescription-drug-costs-80-percent-2070726
